This characteristic was significantly correlated with sensitivity to PARP inhibitor-mediated radiosensitization (observed in approximately 30% of patient samples with tumor-specific expression), providing a novel biomarker for individualized treatment (46). The gene discussed is PARP1; the disease is neoplasm.